TL1A Pathway: Embarking on New Frontiers in IBD Therapy with Biocytogen’s Humanized Mice
January 28, 2025
On December 17, Sanofi’s TL1A antibody, duvakitug, demonstrated success in a Phase IIb study, improving clinical remission rates in patients with moderate to severe ulcerative colitis and Crohn’s disease. Currently, several TL1A inhibitors—including monoclonal and bispecific antibodies such as tulisokibart, PF-07261271, and FG-M701—are in development to address unmet needs in the treatment of inflammatory bowel […]